Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 27, 2024; 16(7): 1039-1050
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1039
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.1039
Immunoprophylaxis failure and vaccine response in infants born to mothers with chronic hepatitis B infection in Djibouti
Sahal Darar Dirir, Laboratoire Medical de la Caisse National de Sécurité Social de Djibouti, Caisse National de Sécurité Social de Djibouti, Djibouti BP 696, Senegal
Ambroise D Ahouidi, Parasitology, Institut de Recherche en santé de Surveillance épidémiologique et de Formation, Dakar 7325, Senegal
Aboubacry Drame, Ecole Doctoral, Université Alioune Diop de Bambey, Dakar 7325, Senegal
Warsama Osman Abdi, Department of Des Soins, Caisse National de Securite Social, Djibouti 696, Senegal
Guelleh Youssouf Kayad, Centre de Soin, Caisse National de Securite Social, Djibouti 696, Senegal
Mohamed Houmed Aboubakar, Laboratoire Medical Mer Rouge, Djibouti 99399, Senegal
Makhtar Camara, Centre Hospitalier Universitaire Aristide le Dantec, Laboratoire Bactériologie-Virologie-Hôpital Aristide le Dantec, Dakar 7325, Senegal
Coumba Toure Kane, Department of Virology, Institut de Recherche en Santé de Surveillance épidémiologique et de Formation, Dakar 7325, Senegal
Halimatou Diop Ndiaye, Bacteriology and Virology Laboratory, Le Dantec University Teaching Hospital, Dakar BP 7325, Senegal
Author contributions: Darar Dirir S, Ahouidi AD, Houmed Aboubakar M, Camara M, Toure Kane C, and Diop-Ndiaye H conceived the research study; Darar Dirir S, Drame A, and Diop-Ndiaye H analyzed the data and wrote the manuscript; Osman Abdi W and Youssouf Kayad G provided reagents and analytical tools; All authors read and approved the final version of the manuscript.
Supported by the Attestation de Financement de These de Doctorat , Dakar le 28/10/2019.
Institutional review board statement: The study was approved by the Scientific Committee of the Ministry of Health of the Republic of Djibouti under N0 149/DG/INSPD/2023.
Clinical trial registration statement: Not applicable, as the study did not involve randomized clinical trials.
Informed consent statement: All study participants provided informed written consent before study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data source will be shared upon request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Halimatou Diop Ndiaye, BPharm, Professor, Professor Emerita, Bacteriology and Virology Laboratory, Le Dantec University Teaching Hospital, 30 Ave Pasteur, Dakar BP 7325, Senegal. halimatoudiop@yahoo.fr
Received: December 30, 2023
Revised: May 3, 2024
Accepted: June 4, 2024
Published online: July 27, 2024
Processing time: 209 Days and 0.4 Hours
Revised: May 3, 2024
Accepted: June 4, 2024
Published online: July 27, 2024
Processing time: 209 Days and 0.4 Hours
Core Tip
Core Tip: This study evaluated the effectiveness of hepatitis B virus (HBV) vaccination and immunoglobulin administration in infants born to hepatitis B surface antigen-positive mothers. The mother-to-child transmission rate was 4%, increasing to 67% in hepatitis B e antigen (HBeAg)-positive women with a viral load > 200000 IU/mL. A seroprotective response was achieved in 84% of infants, and immunoprophylaxis failure was associated with maternal HBV DNA levels and positive HBeAg status. This combination has been shown to be effective in preventing HBV mother-to-child transmission in HBeAg-negative women and demonstrated the value of peripartum prophylaxis for women at risk.